Aeromonas tecta

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Aeromonas tecta is a Gram-negative, non-spore-forming, facultatively anaerobic, motile, rod-shaped bacterium. It has been detected in at least 2 gut microbiome compilation studies or metastudies. Aeromonas tecta is probably a rare gut coloniser. (Demarta2008)



  • This organism has been recovered from human faeces. Pathogenicity status unknown, or very unlikely to be pathogenic. A possible gut commensal.
    • GENERAL CHARACTERISTICS (Demarta2008);
    Character Response
  • Substrates hydrolysed or digested:
  • casein; gelatin;
  • 🌡
  • Temperature tolerance:
  • doesn't grow at 4℃; doesn't grow at 42℃; Grows optimally at 30℃.
  • H+
  • Acid from carbohydrates usually produced:
  • fructose; glucose; glycerol; arbutin; gluconate; N-Ac glucosamine; salicin;
  • ±
  • Strain-dependent acid from carbs:
  • galactose;
  • ⥅
  • Substrates assimilated or utilised:
  • arbutin; fructose; gluconate; gentiobiose; glucose; glycerol; glycogen; maltose; mannitol; mannose; ribose; salicin; starch; trehalose; histidine; proline; serine; caprate; oxoglutarate;
  • ±
  • Strain-dependent substrate utilisation:
  • alanine; acetate; citrate;
  • Active enzymes:
  • arginine dihydrolase; catalase; β-galactosidase; oxidase;
    • SPECIAL FEATURES (Demarta2008);
    Character Response
  • ✗
  • Metabolites not produced:
  • indole;
  • ✗
  • VP test:
  • not active
  • Haemolysis:
  • beta
  • ✓
  • Nitrate:
  • reduced
    • RESPONSE TO ANTIBIOTICS (Demarta2008); (Goldstein2000); (Goldstein1999a); (Goldstein1999b);
    Class Active Resistant
  • Penicillins:
  • amoxicillin-clavulanic acid; aztreonam; imipenem; piperacillin; piperacillin-tazobactam;
  • amoxicillin; ampicillin; ticarcillin; ticarcillin-clavulanic acid;
  • Cephalosporins:
  • cefepime; cefoperazone; cefotaxime; cefoxitin; ceftazidime;
  • cephalothin;
  • Macrolides:
  • azithromycin; clarithromycin; erythromycin; roxithromycin; telithromycin;
  • Tetracyclines:
  • doxycycline; minocycline; tetracycline;
  • Quinolines:
  • ciprofloxacin; gatifloxacin; gemifloxacin; levofloxacin; moxifloxacin; norfloxacin; sparfloxacin; trovafloxacin;
  • Heterocycles:
  • chloramphenicol; metronidazole; trimethoprim-sulfamethoxazole;
  • Vancomycins:
  • vancomycin;
  • Miscellaneous antibiotics:
  • clindamycin; telithromycin;

  • Demarta, A., Küpfer, M., Riegel, P., Harf-Monteil, C., Tonolla, M., Peduzzi, R., Monera, A., José Saavedra, M., & Martínez-Murcia, A. (2008). Aeromonas tecta sp. nov., isolated from clinical and environmental sources. Systematic and Applied Microbiology, 31(4), 278–286.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Proteobacteria Class:  Gammaproteobacteria Order:  Aeromonadales Family:  Aeromonadaceae Genus:  Aeromonas Gram stain:  neg O2 Relation.:  facultatively anaerobic Spore:  No spore Motility:  Swimming Morphology:  Rod
    Health:  Unknown
    Source:  human faeces
    Opt. T:  30℃
    Low T(℃):  4(neg)
    High T(℃):  42(neg)
    		Aesculin:  vr Urea:  neg Gelatin:  + Casein:  +
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    L-Arabinose:  neg Fructose:  + Galactose:  d(neg) Glucose:  + Rhamnose:  neg Cellubiose:  neg Lactose:  neg Melibiose:  neg Sucrose:  neg Glycerol:  + Sorbitol:  neg Arbutin:  + Gluconate:  + Me-α-D-Glc:  neg NAc-α-GA:  + Salicin:  d(+)
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Arabinose:  neg L-Arabinose:  neg Fructose:  + Fucose:  neg D-Fucose:  neg Galactose:  neg Glucose:  + D-Lyxose:  neg Mannose:  + Rhamnose:  neg Ribose:  + D-Tagatose:  neg Xylose:  neg Cellubiose:  neg Gentiobiose:  + Lactose:  neg Maltose:  + Melezitose:  neg Melibiose:  neg Raffinose:  neg Sucrose:  neg D-Turanose:  neg Trehalose:  + Adonitol:  neg Amygdalin:  neg D-Arabitol:  neg L-Arabitol:  neg Arbutin:  + Dulcitol:  neg Erythritol:  neg Gluconate:  + Glycerol:  + Glycogen:  + Inositol:  neg Inulin:  neg Mannitol:  + Me-α-D-Glc:  neg Salicin:  + Sorbitol:  neg Starch:  + Xylitol:  neg Ala:  d His:  + Pro:  + Ser:  + Acetate:  d Caprate:  + Citrate:  d 3-Hydroxybutyrate:  neg 3-Hydroxybenzoate:  neg 4-Hydroxybenzoate:  neg Itaconate:  neg 2-Ketogluconate:  neg 5-Ketogluconate:  neg DL-Lactate:  neg Malonate:  neg Propionate:  neg Suberate:  neg Valerate:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Oxidase:  + Catalase:  + Urease:  neg β-Galactosidase:  + ArgDH:  + LysDC:  vr OrnDC:  neg GluGluAA:  vr
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    amoxicillin:  R(10; disc)
    Augmentin:  S(MIC50): 0.06, MIC90: 0.5, RNG: (0.03–0.5)
    ampicillin:  R(10; disc)
    aztreonam:  S(30; disc)
    penicillin_G:  Var(MIC50): 0.03, MIC90: 16, RNG: (≤0.015–32)
    piperacillin:  S(100; disc)
    piper-taz:  S(110; disc)
    ticarcillin:  R(75; disc)
    tica-clav:  R(85; disc)
    imipenem:  S(10; disc)
    cefepime:  S(30)
    cefoperazone:  S(30; disc)
    cefotaxime:  S(MIC50): 0.06, MIC90: 8, RNG: (0.03–16)
    cefoxitin:  S(30; disc)
    ceftazidime:  S(; disc)
    cephalothin:  R(30; disc)
    amikacin:  Var(MIC50): 30; disc), MIC90: Var(30; disc
    gentamicin:  Var(MIC50): 10; disc), MIC90: Var(10; disc
    kanamycin:  Var(MIC50): 30; disc), MIC90: Var(30; disc
    tobramycin:  Var(MIC50): 10; disc), MIC90: Var(10; disc
    azithromycin:  S(MIC50): 1, MIC90: 2, RNG: (0.5–2)
    erythromycin:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.25–1)
    clarithromycin:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.125)
    roxithromycin:  S(MIC50): 1, MIC90: 1, RNG: (0.5–1)
    telithromycin:  S(MIC50): 0.25, MIC90: 0.5, RNG: (0.125–0.5)
    ciprofloxacin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.5–4)
    gatifloxacin:  S(MIC50): 0.125, MIC90: 0.125, RNG: (0.06–0.5)
    gemifloxacin:  S(MIC50): 0.125, MIC90: 0.25, RNG: (0.06–8)
    levofloxacin:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.25–1)
    moxifloxacin:  S(MIC50): 0.06, MIC90: 0.25, RNG: (0.03–0.25)
    norfloxacin:  S(10; disc)
    sparfloxacin:  S(MIC50): 0.5, MIC90: 1, RNG: (0.25–2)
    trovafloxacin:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.03–0.125)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    doxycycline:  S(MIC50): 0.06, MIC90: 0.125, RNG: (0.06–4)
    minocycline:  S(MIC50): 0.06, MIC90: 0.06, RNG: (0.03–4)
    tetracycline:  S(MIC50): 0.25, MIC90: 0.25, RNG: (0.125–16)
    vancomycin:  S(MIC50): 0.8, MIC90: 0.8, RNG: (0.8)
    chloramphenicol:  S(30; disc)
    metronidazole:  S(MIC50): 0.5, MIC90: 0.5, RNG: (0.125–2)
    SXT:  S(25; disc)
    clindamycin:  S(MIC50): ≤0.015, MIC90: ≤0.015, RNG: (≤0.015–0.125)

    References

    SPECIFIC REFERENCES FOR AEROMONAS TECTA
  • Demarta2008 - Aeromonas tecta sp. nov., isolated from clinical and environmental sources.
  • Goldstein2000 - Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
  • Goldstein1999a - Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections.
  • Goldstein1999b - Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR AEROMONAS TECTA
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • ...............................
    • Added: April 08, 2021